Ajanta Pharma Ltd.

BSE: AJANTPHARM532331ISIN INE031B01049

Healthcare
Pharmaceuticals
BSE 500

Share price

₹3,313.55-4.20 (-0.13%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹3,796.95
52W low: ₹2,446.35
Off 52W high: -12.73%
1M return: -5.01%
3M return: -3.63%
6M return: +7.12%
1Y return: +26.89%
20D avg volume: 24,218
50 DMA: ₹3,472.97
200 DMA: ₹3,173.08

Key ratios Consolidated

Market cap: ₹41,406 Cr
Current price: ₹3,313.55
52W high / low: ₹3,796.95 / ₹2,446.35
Face value: ₹2.00
P/E: 32.79
P/B: 8.55
EPS (TTM): ₹101.06
Book value / share: ₹387.58
ROE: —
ROCE: 29.40%
Operating margin: —
Net margin: —
Debt / equity: 0.05
Net debt: ₹108.73 Cr
Interest cover: 86.52
Dividend yield: 1.81%
Dividend / share (TTM): ₹60.00
Payout: 59.37%
Cash conversion cycle: 150.5 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	1,794	1,626	1,422	1,375	1,354	1,303	1,170	1,146	1,187	1,145	1,054	1,105
	37.39	70.90	61.43	24.97	59.34	26.33	18.11	30.44	19.48	26.47	35.50	13.59
	1,832	1,697	1,483	1,400	1,413	1,329	1,189	1,177	1,206	1,171	1,090	1,119
	1,296	1,250	1,136	1,041	1,072	997.85	919.11	869.18	915.88	849.27	811.54	827.83
	348.97	296.51	256.76	235.07	217.60	207.08	190.96	210.14	207.09	238.41	259.03	239.05
	80.89	66.92	71.35	53.55	53.26	51.63	80.18	78.55	45.79	45.28	40.44	39.29
	383.69	381.11	340.72	330.52	317.01	302.90	279.78	265.17	260.96	283.78	233.51	231.35
	2.24	3.18	2.36	5.10	3.39	5.26	6.07	7.91	6.02	0.73	1.53	2.49
	47.56	44.50	45.37	43.51	42.97	41.29	39.78	35.97	34.39	33.97	34.25	34.26
	477.80	493.42	442.70	375.82	392.08	372.52	310.06	302.32	352.83	262.94	277.87	265.56
	535.15	446.80	347.11	358.60	340.81	331.13	269.41	307.39	290.24	322.12	278.04	290.91
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	535.15	446.80	347.11	358.60	340.81	331.13	269.41	307.39	290.24	322.12	278.04	290.91
	147.01	112.58	80.41	84.83	80.62	75.79	44.15	74.51	73.76	76.35	75.32	80.88
	388.14	334.22	266.70	273.77	260.19	255.34	225.26	232.88	216.48	245.77	202.72	210.03
	31.07	26.75	21.35	21.91	20.83	20.44	18.00	18.60	17.27	19.54	16.10	16.68
Key metrics
	584.95	494.48	394.84	407.21	387.17	377.68	315.26	351.27	330.65	356.82	313.82	327.66
	32.60%	30.40%	27.80%	29.60%	28.60%	29.00%	26.90%	30.60%	27.90%	31.20%	29.80%	29.60%
	21.60%	20.60%	18.80%	19.90%	19.20%	19.60%	19.20%	20.30%	18.20%	21.50%	19.20%	19.00%
	10.60%	—	7.40%	—	7.60%	—	6.90%	—	—	—	—	—
	32.50%	24.80%	21.50%	20.00%	14.10%	13.80%	11.00%	3.70%	—	—	—	—
	49.20%	30.90%	18.40%	17.60%	20.20%	3.90%	11.10%	10.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	6,217	5,453	4,648	4,209	3,743	3,341	2,890	2,588	2,055	2,131
	194.69	172.07	94.50	84.60	98.64	115.68	25.98	92.19	21.08	24.16
	6,411	5,625	4,743	4,293	3,841	3,457	2,916	2,680	2,076	2,155
	4,724	4,247	3,553	3,179	3,096	2,547	2,015	2,012	1,562	1,532
	1,137	916.51	846.60	939.43	878.36	779.34	706.41	560.33	391.84	378.28
	272.71	229.79	249.80	166.35	146.28	136.10	89.54	112.13	48.25	77.35
	1,436	1,291	1,090	900.34	785.14	645.78	548.25	485.59	430.71	376.47
	12.88	16.11	20.73	7.21	5.84	10.20	8.27	11.91	1.16	0.41
	180.94	173.14	144.11	135.40	130.80	125.30	116.09	95.72	72.08	—
	1,790	1,583	1,228	1,070	1,124	933.64	697.83	763.24	674.75	689.59
	1,688	1,378	1,189	1,114	745.25	909.48	900.18	667.89	514.27	622.55
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.92	0.00	0.00
	1,688	1,378	1,189	1,114	745.25	909.48	900.18	663.97	514.27	622.55
	424.83	321.65	268.77	297.76	157.27	196.80	246.31	196.27	127.30	153.91
	1,263	1,056	920.39	816.17	587.98	712.68	653.87	467.70	386.97	468.64
	101.08	84.53	73.56	64.82	45.89	82.45	75.09	53.60	43.97	—
Key metrics
	1,881	1,567	1,354	1,257	881.89	1,045	1,025	771.60	587.51	622.96
	30.27%	28.70%	29.10%	29.90%	23.60%	31.30%	35.50%	29.80%	28.60%	29.20%
	20.31%	19.40%	19.80%	19.40%	15.70%	21.30%	22.60%	18.10%	18.80%	22.00%
	—	29.40%	30.10%	—	—	—	—	—	—	—
	25.01%	17.30%	10.40%	12.50%	12.00%	15.60%	11.70%	25.90%	-3.50%	—
	29.70%	14.70%	12.80%	38.80%	-17.50%	9.00%	39.80%	20.90%	-17.40%	—
	—	164.03	839.31	—	—	—	—	—	—	—
	—	0.50	1.26	—	—	—	—	—	—	—
	—	0.05	0.00	—	—	—	—	—	—	—
	—	108.73	-172.53	—	—	—	—	—	—	—
	—	150.5	128.2	—	—	—	—	—	—	—
Balance sheet
	—	6,155	5,015	—	—	—	—	—	—	—
	—	3,735	2,830	—	—	—	—	—	—	—
	—	103.26	175.12	—	—	—	—	—	—	—
	—	1,854	1,183	—	—	—	—	—	—	—
	—	938.54	903.85	—	—	—	—	—	—	—
	—	267.73	123.30	—	—	—	—	—	—	—
	—	1,726	1,625	—	—	—	—	—	—	—
	—	544.30	454.20	—	—	—	—	—	—	—
	—	1,416	996.10	—	—	—	—	—	—	—
	—	211.99	2.59	—	—	—	—	—	—	—
	—	211.99	2.59	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	4,527	3,790	—	—	—	—	—	—	—
Cash flow
	—	529.19	1,157	—	—	—	—	—	—	—
	—	-428.92	-376.52	—	—	—	—	—	—	—
	—	-167.92	-733.41	—	—	—	—	—	—	—
	—	365.16	317.92	—	—	—	—	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	1,725	1,489	1,211	1,207	1,220	1,209	1,014	1,102	1,129	1,077	926.07	1,085
	52.62	70.82	62.98	25.76	75.03	40.63	17.93	33.23	40.34	28.37	33.68	13.73
	1,778	1,559	1,274	1,232	1,295	1,249	1,032	1,135	1,169	1,106	959.75	1,099
	1,255	1,136	1,016	909.89	973.30	920.20	803.72	803.00	860.05	795.08	733.81	793.88
	348.97	296.51	256.77	235.07	217.60	207.08	190.96	210.14	207.09	238.41	259.03	239.04
	74.43	67.20	57.99	57.89	51.89	50.29	56.54	40.23	42.62	44.61	40.26	37.64
	355.14	352.81	313.49	306.16	293.44	280.96	257.86	245.71	241.65	265.68	215.97	216.41
	0.79	0.76	0.74	1.87	0.73	0.73	0.67	2.48	0.73	0.72	1.42	2.36
	46.30	43.31	44.16	42.38	41.92	40.31	38.76	34.93	33.32	32.92	33.47	33.41
	435.94	422.51	393.79	304.75	343.33	334.75	274.03	265.51	317.04	237.82	243.08	234.01
	522.62	423.45	257.61	322.46	321.97	328.99	228.15	332.15	309.20	310.56	225.94	305.14
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	522.62	423.45	257.61	322.46	321.97	328.99	228.15	332.15	309.20	310.56	225.94	305.14
	142.73	107.98	60.33	77.42	72.44	74.02	34.72	79.70	74.22	74.53	63.25	84.99
	379.89	315.47	197.28	245.04	249.53	254.97	193.43	252.45	234.98	236.03	162.69	220.15
	30.40	25.25	15.79	19.61	19.98	20.41	15.46	20.16	18.75	18.77	12.92	17.48
Key metrics
	569.71	467.52	302.51	366.71	364.62	370.03	267.58	369.56	343.25	344.20	260.83	340.91
	33.00%	31.40%	25.00%	30.40%	29.90%	30.60%	26.40%	33.50%	30.40%	32.00%	28.20%	31.40%
	22.00%	21.20%	16.30%	20.30%	20.40%	21.10%	19.10%	22.90%	20.80%	21.90%	17.60%	20.30%
	11.00%	—	5.80%	—	7.50%	—	6.00%	—	—	—	—	—
	41.40%	23.20%	19.40%	9.50%	8.10%	12.20%	9.50%	1.50%	—	—	—	—
	52.20%	23.70%	2.00%	-2.90%	6.20%	8.00%	18.90%	14.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	5,631	4,846	4,322	3,971	3,411	3,141	2,719	2,196	1,773	1,830
	212.18	204.40	119.87	116.48	132.75	139.73	103.57	184.20	102.15	73.01
	5,843	5,050	4,442	4,088	3,544	3,280	2,822	2,381	1,875	1,903
	4,317	3,819	3,262	2,991	2,844	2,380	1,920	1,764	1,362	1,341
	1,137	916.52	846.60	939.43	878.36	773.04	704.09	556.22	388.71	375.43
	257.51	218.06	184.00	162.16	149.04	116.12	100.59	98.73	70.79	73.01
	1,328	1,194	1,011	834.16	720.41	585.87	498.11	437.82	389.37	342.89
	4.16	2.59	4.60	6.80	5.23	9.12	6.90	9.10	0.41	0.24
	176.15	168.77	139.93	132.16	126.95	120.96	111.49	91.29	69.90	57.14
	1,557	1,377	1,094	938.11	986.17	831.32	573.49	561.85	509.92	541.46
	1,526	1,231	1,180	1,097	699.85	900.54	902.09	616.59	513.05	562.44
	0.00	0.00	0.00	—	—	—	—	-3.92	—	—
	1,526	1,231	1,180	1,097	699.85	900.54	902.09	612.67	513.05	562.44
	388.46	284.21	263.17	289.71	141.13	180.68	226.45	171.54	121.29	134.92
	1,138	946.82	916.89	807.24	558.72	719.86	675.64	441.13	391.76	427.52
	91.05	75.79	73.28	64.11	43.61	83.28	77.59	50.55	44.51	—
Key metrics
	1,706	1,402	1,325	1,236	832.03	1,031	1,020	713.06	583.36	619.82
	30.31%	28.90%	30.60%	31.10%	24.40%	32.80%	37.50%	32.50%	32.90%	33.90%
	20.20%	19.50%	21.20%	20.30%	16.40%	22.90%	24.90%	20.10%	22.10%	23.40%
	—	27.90%	30.80%	—	—	—	—	—	—	—
	23.90%	12.10%	8.80%	16.40%	8.60%	15.50%	23.80%	23.90%	-3.20%	—
	19.71%	3.30%	13.60%	44.50%	-22.40%	6.50%	53.20%	12.60%	-8.40%	—
	—	436.55	736.60	—	—	—	—	—	—	—
	—	0.85	1.15	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	-89.04	-48.60	—	—	—	—	—	—	—
	—	131.0	135.0	—	—	—	—	—	—	—
Balance sheet
	—	5,317	4,554	—	—	—	—	—	—	—
	—	3,119	2,567	—	—	—	—	—	—	—
	—	89.04	48.60	—	—	—	—	—	—	—
	—	1,366	1,226	—	—	—	—	—	—	—
	—	844.71	739.29	—	—	—	—	—	—	—
	—	247.12	108.82	—	—	—	—	—	—	—
	—	1,723	1,622	—	—	—	—	—	—	—
	—	471.85	366.27	—	—	—	—	—	—	—
	—	891.03	710.72	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	4,224	3,625	—	—	—	—	—	—	—
Cash flow
	—	803.83	1,054	—	—	—	—	—	—	—
	—	-399.55	-349.60	—	—	—	—	—	—	—
	—	-359.62	-715.71	—	—	—	—	—	—	—
	—	367.28	317.20	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +12.41%
Sales CAGR 5Y: +12.26%
Profit CAGR 3Y: +19.22%
Profit CAGR 5Y: +6.98%
Sales YoY (TTM): +23.90%
Profit YoY (TTM): +19.71%

Consolidated

Sales CAGR 3Y: +13.37%
Sales CAGR 5Y: +13.54%
Profit CAGR 3Y: +21.55%
Profit CAGR 5Y: +10.06%
Sales YoY (TTM): +25.01%
Profit YoY (TTM): +29.70%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 63.47%

Quarter	September 2026	June 2026
Promoter %	63.47%	63.49%

Holder	Type	Holding	Previous	Change
Rajesh M Agrawal, trustee Rajesh Agrawal Trust	Promoter	14.47%	14.47%	0.00%
Yogesh M Agrawal, trustee Yogesh Agrawal Trust	Promoter	14.47%	14.47%	0.00%
Aayush M Agrawal, trustee Aayush Agrawal Trust	Promoter	11.29%	11.30%	-0.01%
Ravi P Agrawal, trustee Ravi Agrawal Trust	Promoter	10.24%	10.24%	0.00%
Gabs Investments Pvt Ltd	Promoter Group	10.07%	10.08%	-0.01%
Kotak Flexicap Fund	Public	3.22%	3.28%	-0.06%
Uti-Flexi Cap Fund	Public	2.97%	3.11%	-0.14%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	Public	2.79%	2.78%	+0.01%
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	Promoter Group	2.68%	2.68%	0.00%
Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Midcap Fund	Public	2.22%	—	—
Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110	Public	1.91%	1.90%	+0.01%
Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund	Public	1.40%	1.46%	-0.06%
Hdfc Large And Mid Cap Fund	Public	1.01%	1.14%	-0.13%
Ravi P Agrawal	Promoter	0.23%	0.23%	0.00%
Aayush M Agrawal	Promoter	0.02%	0.02%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Pls find enclosed Earnings Call Written Transcript4 Nov 2026 · Company Update / Earnings Call Transcript
Pls find enclosed newspaper publication of financial results for the quarter ended 30.09.2026.2 Nov 2026 · Company Update / Newspaper Publication
Pls find enclosed Audio recording of Earnings Call30 Oct 2026 · Company Update / Analyst / Investor Meet
Pls find enclosed results for the quarter ended 30.09.2026.30 Oct 2026 · Result / Financial Results
Pls find enclosed Financial Results for the quarter ended 30.09.2026.30 Oct 2026 · Board Meeting / Outcome of Board Meeting
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee ....21 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pls find enclosed Earnings Conference Call Intimation.15 Oct 2026 · Company Update / Analyst / Investor Meet
Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve Unaudited consolidated and standalone ....15 Oct 2026 · Board Meeting / Board Meeting
Pls find enclosed Certificate as per Reg 74(5) of SEBI (DP) Regulations.7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 06, 2026 for Aayush Agrawal, trustee ....6 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship Ltd1 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Pls find enclosed herewith Sustainability Report for FY 2026.30 Sep 2026 · Company Update / General
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 28, 2026 for Aayush Agrawal, ....28 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pls find enclosed herewith closure of trading window intimation25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 18, 2026 for Aayush Agrawal, ....18 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pls find enclosed Intimation w.r.t Participation in Investor Conference.31 Aug 2026 · Company Update / General
Pls find enclosed newspaper publication for transfer of equity shares to IEPF.31 Aug 2026 · Company Update / Newspaper Publication
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 27, 2026 for Aayush Agrawal, trustee ....27 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 19, 2026 for Ravi Agrawal, trustee ....19 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Ravi Agrawal, trustee ....14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pls find enclosed Intimation w.r.t participation in Investor Conference5 Aug 2026 · Company Update / General
Pls find enclosed herewith Earning Call Transcript3 Aug 2026 · Company Update / Earnings Call Transcript
Pls find enclosed newspaper publication of financial results for the quarter ended 30.06.2026.31 Jul 2026 · Company Update / Newspaper Publication
Pls find enclosed Audio Recording of Earnings Call30 Jul 2026 · Company Update / Analyst / Investor Meet
Pls find enclosed ESOP Allotment30 Jul 2026 · Company Update / Allotment of ESOP / ESPS
PFA record date intimation30 Jul 2026 · Corp. Action / Record Date
PFA Dividend Intimation30 Jul 2026 · Corp. Action / Dividend
Results of 30.06.2026.30 Jul 2026 · Result / Financial Results
Board Meeting Outcome30 Jul 2026 · Board Meeting / Outcome of Board Meeting
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 29, 2026 for Aayush Agrawal, trustee ....29 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pls find enclosed Revised Investor Call Intimation21 Jul 2026 · Company Update / Analyst / Investor Meet
Pls fine enclosed Investor Call Intimation20 Jul 2026 · Company Update / Analyst / Investor Meet
Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve Update on board meeting20 Jul 2026 · Board Meeting / Board Meeting
Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve Financial Results for the quarter ....20 Jul 2026 · Board Meeting / Board Meeting
Pls find enclosed voting and scrutinizer''s report w.r.t to 47th AGM held on 16.07.2026.17 Jul 2026 · AGM/EGM / AGM
Pls find enclosed AGM Proceedings16 Jul 2026 · AGM/EGM / AGM
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 14, 2026 for Ravi Agrawal, trustee ....14 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 08, 2026 for Aayush Agrawal, ....8 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pls find enclosed Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.06.2026.7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship Ltd3 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 32.0000	5 Aug 2026	5 Aug 2026	—
Interim Dividend - Rs. - 28.0000	10 Nov 2025	10 Nov 2025	—
Interim Dividend - Rs. - 28.0000	6 Nov 2024	6 Nov 2024	—

Board meetings

30 Oct 2026 Board Meeting - Financial Results
30 Jul 2026 Board Meeting - Financial Results